About Precision IO Group
Precision IO makes tools that help physicians treat cancer with less invasive procedures. The group was formed by combining two companies with complementary technologies.
The company operates from Miami and is led by CEO Kurt Azarbarzin. It is the parent of Quantum Surgical and NeuWave Medical.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | Oct 19, 2026 | $8,542,758fully sold | 2 | $4.2M | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Precision IO Group
The company develops minimally invasive cancer-treatment technology for physicians. It operates through two subsidiaries with complementary capabilities. The investment case depends on turning that combined base into products for more procedures and locations.
The problem it targets
Precision IO targets geographic barriers that limit access to expert cancer care. It is developing telerobotics for work performed across distance. Precision IO argues that remote intervention can extend specialist support to more locations.
What the product does
Epione is the group’s robotic platform for minimally invasive cancer procedures. Precision IO is developing that system alongside a remote intervention program. The program adds telerobotics capabilities for robotic work across distance.
Progress so far
In 2026, Precision IO launched EPIOS, a U.S. clinical study of Epione for bone lesions. The study evaluates the system’s safety. The group also planned to present Epione and its remote program at the Society of Robotic Surgery annual meeting.
We wrote this summary from public statements by Precision IO Group and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Precision IO Group's Form D filed Oct 19, 2026.
Earlier filings also listed Bertin Nahum (executive officer and director, last listed Sep 2025).
Sources
- SECPrecision IO Group Inc. filing history
- CompanyQuantum Surgical Acquires NeuWave Medical, Inc.
- CompanyPrecision IO Group Launches U.S. Clinical Study of Epione
- CompanyPrecision IO to Unveil New Epione Robotic Platform Features
- PressPrecision IO Group to Present Epione Robotic Platform and Remote Intervention Program
- PressPrecision IO Group Launches U.S. Clinical Study of Epione